HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Aclaris Therapeutics (NASDAQ: ACRS) and maintained a price target of $16 for the stock.